Pathologic factors that are known to confer a negative prognostic impact in patients with PDAC include high pathologic primary tumor (pT) stage [16–18], poor tumor differentiation [16, 19–21], positive lymph node status [16, 18, 20–24] etc. Our study identified ASS1 as a new prognostic factor in patients with PDAC in two large independent cohorts of patients: 135 patients who underwent upfront PD without neoadjuvant therapy (untreated cohort) and 122 patients received pre-operative neoadjuvant therapy and PD (treated cohort). The gene discussed is ASS1; the disease is neoplasm.